Press releases - Ypsomed

Ypsomed expands its options

01.07.2021 - 07:00 Press Releases Ypsomed Group

Burgdorf – The Annual General Meeting of the Ypsomed Group on 30 June 2021 approved all proposals of the Board of Directors. The AGM elected Ms Betül Susamis Unaran as a new member of the Board of Directors and authorised the Board to increase the share capital.

Topics:

Management

Alliance to Zero founded to achieve net zero emissions across the pharmaceutical supply chain

02.06.2021 - 10:00 Press Releases Ypsomed Group

Burgdorf – Today, eight companies representing the pharmaceutical supply chain for pharma products announced the founding of the Alliance to Zero, a non-profit membership association for pharma and biotech supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net zero emissions in line with the goals of the Paris Climate Agreement.

Topics:

Responsibility & Engagement

Ypsomed continues to invest in growth

26.05.2021 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased its consolidated sales by CHF 9.4 million to CHF 403.7 million in the financial year 2020/21 (prior year: CHF 394.3 million). The two business segments developed differently during the Corona pandemic: while the business with pens and autoinjectors was encouraging, the sales of insulin pumps remained at a low level. Ypsomed has set an important course in the financial year 2020/21 to improve the sales opportunities for YpsoPump. The increased importance of self-treatment of chronic diseases has reinforced the company’s growth strategy. Ypsomed has therefore advanced all strategic initiatives and further improved its own competitive position. The company invested a total of CHF 142.7 million for this purpose while at the same time creating 110 new jobs. To expand financial flexibility for the future, the Board of Directors will propose an authorised increase in capital at the Annual General Meeting.

Topics:

Access & Expansion

Ypsomed reaches agreement in legal dispute with Insulet

04.01.2021 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) has reached an agreement in its legal dispute with Insulet Corp. (NASDAQ: PODD). Insulet acknowledges the contractually agreed fee and compensates Ypsomed for the termination of the cooperation with an additional USD 36.15 million. The total compensation thus amounts to USD 41.25 million. At the same time, Insulet drops its counterclaim of USD 18.7 million.

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

19.11.2020 - 07:00 Press Releases Ypsomed Group

Burgdorf / Indianapolis – Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.